In an interview at the SNMMI 2024 conference, Oliver Sartor, M.D. discussed key findings from new award-winning research evaluating the potential of Pluvicto in treating patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC).
The radiopharmaceutical agent (177Lu)Lu-PSMA-617 (Pluvicto, Novartis) may be a viable option in the treatment of patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), according to emerging research findings presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
In an interview at the SNMMI conference, Oliver Sartor, MD, said there are reimbursement challenges as well as mixed results with current androgen receptor pathway inhibitor (ARPI) treatment in this patient population.
“We know (ARPI therapy) is a viable alternative, but we also know these patients will progress and go on to need additional therapy,” noted Dr. Sartor, the director of radiopharmaceutical trials at the Mayo Clinic in Rochester, Minnesota.
In new research, which garnered Abstract of the Year honors at the SNMMI conference, researchers compared the use of Pluvicto versus a change in ARPI therapy (abiraterone or enzalutamide) in 468 taxane-naïve patients with mCRPC.
In the primary study analysis, the researchers found that patients in the Pluvicto group had a significantly higher median radiographic progression-free survival in comparison to those in the ARPI change group (9.3 months vs. 5.55 months). A second interim analysis revealed that patients in the Pluvicto group had over a 35 percent higher objective response rate (50.7 percent vs. 14.9 percent) and a significantly longer median time to PSA progression (10.55 months vs. 4.24 months) in contrast to patients in the ARPI change cohort.
Dr. Sartor, a co-author of the study, also noted that the second interim analysis showed a lower incidence of grade > 3 adverse events in patients receiving Pluvicto.
(Editor’s note: For related content, see “Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD,” “SNMMI: PSMA-18F DCFPyL Changes Treatment for PCa Recurrence in Significant Number of Patients with Low PSAs” and “Study: PSMA PET/CT Agent May Rule Out csPCa in 93 Percent of PI-RADS 3 Lesions.”)
While Pluvicto was approved by the FDA for patients with PSMA-positive mRCPC who previously had ARPI therapy and taxane-based chemotherapy, Dr. Sartor suggested there is “reasonable hope” for an expanded indication for Pluvicto in the management of patients with taxane-naïve mRCPC.
“If the FDA does give an approval, it will truly be practice-changing, Insurances will cover it and patients can be treated,” added Dr. Sartor.
For more insights from Dr. Sartor, watch the video below.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
CT Perfusion Study Shows Enhanced Detection of Medium Vessel Occlusions with Emerging AI Software
May 21st 2025The Rapid CTP AI software offered 23 percent greater detection of medium vessel occlusions in comparison to the Viz CTP AI software, according to research presented at the European Stroke (Organization) Conference (ESOC).